Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions

 
• By Sue Sutter
FDA Advisory Committee Feature image
Palforzia garnered favorable AdComm votes on efficacy and safety.

More from US FDA Performance Tracker

More from Regulatory Trackers